Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 23;16(3):305.
doi: 10.3390/ijerph16030305.

Health-Related Quality of Life Impairment among Patients with Different Skin Diseases in Vietnam: A Cross-Sectional Study

Affiliations

Health-Related Quality of Life Impairment among Patients with Different Skin Diseases in Vietnam: A Cross-Sectional Study

Sau Huu Nguyen et al. Int J Environ Res Public Health. .

Abstract

Skin diseases have caused a heavy burden on the infected population worldwide. This study aimed to examine the health-related quality of life (HRQOL) among patients with different skin diseases and identify associated factors. A cross-sectional study with 430 participants was conducted at the Vietnam National Hospital of Dermatology and Venereology (NHD) from September to November 2018. The EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument was employed, which measures the EQ-5D index from five domains including mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Multivariate Tobit regression was adopted to determine factors that were associated with HRQOL (EQ-5D index). The rate of atopic dermatitis was the highest with 28.8%, following by contact dermatitis (17.0%) and skin fungal infections (13.0%). Regarding HRQOL, anxiety/depression was the most common health problem in patients with skin diseases (71.8%), following by pain/discomfort (63.6%). The mean EQ-5D index score was 0.73 (SD = 0.19). The lowest EQ-5D index scores were obtained for females with skin infections (mean = 0.52) and for males with psoriasis (mean = 0.59). Females had significantly lower scores compared to males (Coef. = -0.06; 95% CI = -0.11 to -0.01). Higher income and living in rural areas were also negatively correlated with the EQ-5D index. This study demonstrated the low HRQOL among patients with skin diseases in Vietnam and emphasized the vulnerability of patients with different socioeconomic statuses to their HRQOL.

Keywords: Vietnam; dermatology; health-related quality of life; skin disorder; socioeconomic status.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Percentage of patients reporting any problems in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) dimensions according to different dermatology disorders.
Figure 2
Figure 2
EQ-5D index according to gender and different dermatology disorders.

Similar articles

Cited by

References

    1. Hay R., Bendeck S.E., Chen S., Estrada R., Haddix A., McLeod T., Mahe A. Skin Diseases. In: Jamison D.T., Breman J.G., Measham A.R., Alleyne G., Claeson M., Evans D.B., Jha P., Mills A., Musgrove P., editors. Disease Control Priorities in Developing Countries. The World Bank; Washington, DC, USA: 2006. - PubMed
    1. Karimkhani C., Dellavalle R.P., Coffeng L.E., Flohr C., Hay R.J., Langan S.M., Nsoesie E.O., Ferrari A.J., Erskine H.E., Silverberg J.I., et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153:406–412. doi: 10.1001/jamadermatol.2016.5538. - DOI - PMC - PubMed
    1. Seth D., Cheldize K., Brown D., Freeman E.F. Global Burden of Skin Disease: Inequities and Innovations. Curr. Dermatol. Rep. 2017;6:204–210. doi: 10.1007/s13671-017-0192-7. - DOI - PMC - PubMed
    1. Hahnel E., Lichterfeld A., Blume-Peytavi U., Kottner J. The epidemiology of skin conditions in the aged: A systematic review. J. Tissue Viability. 2017;26:20–28. doi: 10.1016/j.jtv.2016.04.001. - DOI - PubMed
    1. Basra M.K., Shahrukh M. Burden of skin diseases. Expert Rev. Pharmacoecon. Outcomes Res. 2009;9:271–283. doi: 10.1586/erp.09.23. - DOI - PubMed